March 4, 2022
Health Affairs Forefront recently published insight from their short series, “Prescription Drugs: Promoting Affordability and Innovation,” a conference hosted by Rena Conti, Associate Professor of Markets, Public Policy, and Law.
The conference focused on a research and policy agenda to support both drug affordability and innovation, discussing topics related to drug development, access, and efficacy. The article details the importance of addressing the threat of antimicrobial resistance (AMR), explaining that this resistance occurs when microorganisms undergo changes that render medicines used to treat them ineffective, leaving patients vulnerable to illness or death. In order to treat patients with resistance infections, physicians need new drugs while also preserving the effectiveness of existing antibiotics.
The article elaborates on the challenges that AMR presents to pharmaceutical companies engaging in new drug development. In this series, the authors discuss why recent initiatives to develop new antibacterials have not been successful. It is argued that current initiatives focused on push and pull incentives as well as developing global partnerships across governments and commercial entities hold great promise for addressing AMR.
- Insights Interview: Competition and Management Theory – Richard D’Aveni (QUESTROM MBA ’79)
- [WalletHub] 2022’s Best Coffee Cities in America
- Have we forgotten the true meaning of Labor Day?
- [Inside Higher Ed] Getting Through a Job Search with More than a Job
- [Boston Herald] Unemployment Rate Increases as Job Growth Slows
- [Radio Health Journal] Offshoring Medication: Where Are Your Generic Drugs Being Made?
- Expert Take: Oil Market Volatility
- Worried About Back-to-School Inflation? Latest Price Data on Backpacks, Laptops, and Kids’ Clothes Offers Some Relief for Parents
- [AP] Airlines Pushed by Labor Unions to SPend Money on Hiring Rather Than on Stock Buybacks
- [Reuters]Newly Launched U.S. Drugs Head Toward Record-High Prices in 2022